B. Riley analyst Mayank Mamtani downgraded Novavax to Neutral from Buy with a price target of $10, down from $29.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVAX:
- Novavax Tanks on Disappointing Q4; To Focus on Lowering Costs
- Novavax says ‘substantial doubt exists’ on ability to continue as going concern
- Novavax reports Q4 EPS ($2.28), consensus (92c)
- Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
- Novavax call volume above normal and directionally bullish
